HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (3- fluoro- 2- methylphenyl)- 4,5- dihydrooxazol- 2- ylamine

a partial agonist of trace amine-associated receptor 1

Also Known As:

RO5263397

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - 4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine: 8

Experts

1.	Li, Jun-Xu: 4 articles (01/2022 - 10/2017)
2.	Wu, Ruyan: 3 articles (01/2022 - 01/2021)
3.	Zhang, Yanan: 3 articles (01/2022 - 10/2017)
4.	Hoener, Marius C: 3 articles (01/2019 - 02/2015)
5.	Johnson, Bernard: 2 articles (01/2022 - 01/2021)
6.	Liu, Jianfeng: 2 articles (01/2022 - 01/2021)
7.	Huang, Yufei: 1 article (01/2022)
8.	Seaman, Robert: 1 article (01/2021)
9.	Tian, Jingwei: 1 article (01/2021)
10.	Vu, Jimmy: 1 article (01/2021)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 02/01/2015 - "RO5263397 [(S)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine], a new compound that showed promising results in animal models of schizophrenia, is mainly metabolized in humans by N-glucuronidation. "
2.	Polydipsia 01/01/2019 - "Our results have demonstrated that the wide range of RO5263397, the highly selective partial TAAR1 agonist, doses (1-10 mg/kg) attenuated the polydipsia induced by two different schedules of food delivery in rats. "
3.	Chronic Pain 01/01/2021 - "Furthermore, RO5263397 did not affect the analgesic effects of morphine in an acute nociception model in mice and a chronic pain model in rats. "
4.	Substance-Related Disorders (Drug Abuse) 12/01/2021 - "Selective and potent engineered TAAR1 ligands, including full (RO5166017 and RO5256390) and partial (RO5203648, RO5263397 and RO5073012) agonists and the antagonist EPPTB (N-(3-ethoxyphenyl)-4-(1-pyrrolidinyl)-3-(trifluoromethyl) benzamide, RO5212773), serve as invaluable tools for the investigation of TAAR1 functions and display significant potential for the development of TAAR1-based pharmacotherapies for the treatment of substance use disorders. "
5.	Weight Gain 05/01/2013 - "TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation. "

Related Drugs and Biologics

1.	RO5166017
2.	RO5256390
3.	Quinpirole
4.	Nicotine
5.	Morphine (MS Contin)
6.	Ligands
7.	Analgesics (Analgesic Drugs)
8.	Olanzapine (Zyprexa)
9.	4- (3,4- dichlorophenyl)- 4,5- dihydrooxazol- 2- ylamine
10.	(4- chlorophenyl)- (1H- imidazol- 4- ylmethyl)- isopropyl- amine

Related Therapies and Procedures

1.	Self Administration (Administration, Self)
2.	Drug Therapy (Chemotherapy)